Structures by: Wouters J.
Total: 280
Beta-cyclodextrin Aegelinol clathrate hydrate
C42H70O35,C14H14O4,0.25(O2),9.25(H2O),2(O)
Crystals (2012) 2, 4 1441-1454
a=15.4039(12)Å b=15.2813(12)Å c=17.8904(14)Å
α=99.6620(10)° β=113.4230(10)° γ=102.4810(10)°
Aegelinol
C14H14O4
Crystals (2012) 2, 4 1441-1454
a=6.8921(3)Å b=11.4302(9)Å c=44.964(3)Å
α=90.00° β=90.00° γ=90.00°
N-[(2E)-10-(4-chlorophenyl)-3-[(4-chlorophenyl)amino]-2,10-dihydrophenazin-2-ylidene]propan-2-aminium methanol 2-{2-[(2-chloro-6-methylphenyl)amino]phenyl}acetate
C27H23Cl2N4,C14H10Cl2NO2,0.491(CH4O),C0.25H1.02O0.25
CrystEngComm (2020)
a=16.7209(3)Å b=17.2504(5)Å c=27.8319(7)Å
α=90° β=93.438(2)° γ=90°
Pentakis(1-phenylpropan-1-one) bis(N-[(2E)-10-(4-chlorophenyl) -3-[(4-chlorophenyl)amino]-2,10-dihydrophenazin-2-ylidene] propan-2-aminium) bis(2-{2-[(2,6-dichlorophenyl)amino]phenyl} acetate)
2(C27H23Cl2N4),2(C14H10Cl2NO2),5(C9H10O)
CrystEngComm (2020)
a=10.7319(4)Å b=13.6005(6)Å c=21.5496(9)Å
α=73.502(4)° β=77.404(4)° γ=73.540(4)°
Clofaziminium 1+ diclofenac 1- diclofenac salt cocrystal
C27H23Cl2N41,C14H10Cl2NO21,C14H11Cl2NO2
CrystEngComm (2020)
a=11.9326(3)Å b=15.2549(4)Å c=16.0042(4)Å
α=89.161(2)° β=70.570(2)° γ=69.693(2)°
Clofaziminium diclofenac
C27H23Cl2N41,C14H10Cl2NO21
CrystEngComm (2020)
a=12.4461(6)Å b=13.2751(5)Å c=13.3667(6)Å
α=84.423(3)° β=67.963(4)° γ=66.662(4)°
Nonakis(2-hydroxybenzaldehyde) tetrakis(N-[(2E)-10- (4-chlorophenyl)-3-[(4-chlorophenyl)amino]-2,10- dihydrophenazin-2-ylidene]propan-2-aminium) tetrakis(2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate) hydrate
4(C27H23Cl2N4),4(C14H10Cl2NO2),9(C7H6O2),H2O
CrystEngComm (2020)
a=10.4132(5)Å b=21.2266(7)Å c=25.0657(7)Å
α=66.238(3)° β=89.969(3)° γ=86.658(3)°
N-[(2E)-10-(4-chlorophenyl)-3-[(4-chlorophenyl)amino]-2,10- dihydrophenazin-2-ylidene] propan-2-aminium acetonitrile 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate dihydrate
C27H23Cl2N4,C14H10Cl2NO2,C2H3N,2(H2O)
CrystEngComm (2020)
a=11.6515(3)Å b=11.7149(3)Å c=16.0793(4)Å
α=103.558(2)° β=90.461(2)° γ=105.250(2)°
Clofaziminium diclofenac (1-) diclofenac salt cocrystal
C27H23Cl2N41,C14H10Cl2NO21,C14H11Cl2NO2
CrystEngComm (2020)
a=10.8837(2)Å b=14.4737(3)Å c=17.7519(4)Å
α=101.568(2)° β=105.173(2)° γ=94.286(2)°
N-[(2E)-10-(4-chlorophenyl)-3-[(4-chlorophenyl)amino] -2,10-dihydrophenazin-2-ylidene]propan-2-aminium ethanol 2-{2-[(2,6-dichlorophenyl)amino]phenyl}acetate
C27H23Cl2N4,C14H10Cl2NO2,C2H6O
CrystEngComm (2020)
a=12.5818(4)Å b=13.4486(3)Å c=13.5318(3)Å
α=80.291(2)° β=71.638(2)° γ=71.710(2)°
Clofaziminium 1+ diclofenac 1- diclofenac ethylacetate solvate
C27H23Cl2N4,C14H10Cl2NO2,C14H11Cl2NO2,C4H8O2
CrystEngComm (2020)
a=15.0569(4)Å b=15.3773(4)Å c=15.4247(4)Å
α=76.043(2)° β=61.975(3)° γ=63.541(3)°
Pentakis(1-phenylpropan-1-one) bis(N-[(2E)-10-(4-chlorophenyl) -3-[(4-chlorophenyl)amino]-2,10-dihydrophenazin-2-ylidene] propan-2-aminium) bis(2-{2-[(2,6-dichlorophenyl)amino]phenyl} acetate)
2(C27H23Cl2N4),2(C14H10Cl2NO2),5(C9H10O)
CrystEngComm (2020)
a=10.5086(4)Å b=13.4783(5)Å c=21.4224(8)Å
α=73.629(3)° β=76.913(3)° γ=73.271(3)°
Clofaziminium 1+ diclofenac 1- diclofenac acetonitrile solvated cocrystal of salt
C27H23Cl2N4,C14H10Cl2NO2,C14H11Cl2NO2,2(C2H3N)
CrystEngComm (2020)
a=15.0694(11)Å b=15.2735(10)Å c=15.5991(13)Å
α=74.882(7)° β=61.685(8)° γ=64.227(7)°
C22H23NO3
C22H23NO3
Organic & biomolecular chemistry (2006) 4, 21 3898-3900
a=11.945(1)Å b=11.653(2)Å c=16.339(2)Å
α=90.00° β=127.717(7)° γ=90.00°
C24H24N2O4
C24H24N2O4
Organic & biomolecular chemistry (2006) 4, 21 3898-3900
a=17.576(3)Å b=15.667(2)Å c=7.4650(10)Å
α=90.00° β=90.461(11)° γ=90.00°
C87H123N7O9
C87H123N7O9
Organic & biomolecular chemistry (2011) 9, 18 6373-6384
a=16.1331(14)Å b=37.634(3)Å c=17.1581(15)Å
α=90.00° β=98.715(2)° γ=90.00°
CaCl2 Levetiracetam Nicotinamide
C22H36CaN6O6,2(Cl)
Chemical communications (Cambridge, England) (2020) 56, 86 13229-13232
a=11.9243(5)Å b=8.0669(3)Å c=15.4348(7)Å
α=90° β=92.338(4)° γ=90°
CaCl2 Levetiracetam Isonicotinamide
C22H36CaN6O6,2(Cl)
Chemical communications (Cambridge, England) (2020) 56, 86 13229-13232
a=7.93030(11)Å b=15.1768(2)Å c=23.7226(3)Å
α=90° β=90° γ=90°
C72H110Cl4N7O10
C72H110Cl4N7O10
Chemical communications (Cambridge, England) (2016) 52, 98 14109-14112
a=14.6718(5)Å b=22.9104(8)Å c=23.5888(9)Å
α=90° β=104.564(4)° γ=90°
4(C2H4Cl2),C96H144N6O12
4(C2H4Cl2),C96H144N6O12
Chem. Commun. (2017)
a=13.7784(9)Å b=14.3195(7)Å c=16.9560(8)Å
α=97.571(4)° β=109.693(5)° γ=114.255(5)°
C96H144N6O12,4(C2H2Cl4),CO2,8(H2O)
C96H144N6O12,4(C2H2Cl4),CO2,8(H2O)
Chem. Commun. (2017)
a=13.8689(9)Å b=16.6934(13)Å c=16.8118(12)Å
α=109.746(7)° β=102.230(6)° γ=102.209(6)°
C98H132N6O10,F6S,6(C2H2Cl4)
C98H132N6O10,F6S,6(C2H2Cl4)
Chem. Commun. (2017)
a=13.8587(4)Å b=16.6708(5)Å c=16.8553(6)Å
α=109.455(3)° β=102.536(3)° γ=102.194(3)°
RS-naproxen D-proline 1:1 cocrystal, polymorph I
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.1578(5)Å b=5.8278(2)Å c=25.6828(14)Å
α=90° β=98.762(5)° γ=90°
S-naproxen L-proline 1:1 cocrystal, polymorph II
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=16.2991(7)Å b=5.8654(3)Å c=18.6876(9)Å
α=90° β=100.052(4)° γ=90°
RS-naproxen DL-proline 1:1 cocrystal, polymorph I
C14H14O3,C5H9NO2
CrystEngComm (2018) 20, 45 7308
a=9.9964(3)Å b=9.0958(4)Å c=39.9654(15)Å
α=90° β=90° γ=90°
RS-naproxen D-proline 1:1 cocrystal, polymorph II
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.5901(6)Å b=5.7587(3)Å c=51.425(3)Å
α=90° β=90° γ=90°
RS-naproxen L-proline 1:1 cocrystal, polymorph III
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=12.705(2)Å b=5.7631(8)Å c=25.000(5)Å
α=90° β=95.041(11)° γ=90°
S-naproxen ethanol solvate
C14H14O3,C2H6O
CrystEngComm (2018) 20, 45 7308
a=5.9273(2)Å b=8.7713(5)Å c=28.0747(15)Å
α=90° β=90° γ=90°
1:1 RS-naproxen D-proline cocrystal methanol solvate
2(C14H14O3),2(C5H9NO2),CH4O
CrystEngComm (2018) 20, 45 7308
a=12.9532(4)Å b=5.76337(15)Å c=25.2764(6)Å
α=90° β=93.984(3)° γ=90°
S-naproxen DL-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.8836(7)Å b=9.0952(18)Å c=44.047(10)Å
α=90° β=90° γ=90°
S-naproxen DL-proline 1:1 cocrystal
2(C14H14O3),2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=8.84337(19)Å b=5.83510(15)Å c=33.6766(7)Å
α=90° β=91.9839(19)° γ=90°
RS-naproxen DL-proline 1:1 cocrystal, polymorph II
C14H14O3,C5H9NO2
CrystEngComm (2018) 20, 45 7308
a=34.537(4)Å b=9.0077(8)Å c=5.7183(5)Å
α=90° β=90° γ=90°
1:1 S-naproxen DL-proline cocrystal hydrate
2(C14H14O3),2(C5H9NO2),2(H2O1)
CrystEngComm (2018) 20, 45 7308
a=6.06468(13)Å b=12.2629(3)Å c=50.6290(15)Å
α=90° β=90° γ=90°
S-naproxen L-proline 2:3 cocrystal
2(C14H14O3),3(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.70180(10)Å b=18.8609(3)Å c=37.2392(5)Å
α=90° β=90° γ=90°
S-naproxen L-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.88160(7)Å b=8.79809(10)Å c=45.4679(5)Å
α=90° β=90° γ=90°
C19H20NO,Cl
C19H20NO,Cl
CrystEngComm (2018) 20, 24 3318
a=8.3825(4)Å b=14.3515(8)Å c=13.3425(7)Å
α=90° β=96.835(5)° γ=90°
C19H20NO,Br
C19H20NO,Br
CrystEngComm (2018) 20, 24 3318
a=8.3080(4)Å b=13.9039(8)Å c=13.6580(6)Å
α=90° β=96.642(4)° γ=90°
C23H22NO,NO3
C23H22NO,NO3
CrystEngComm (2018) 20, 24 3318
a=14.9120(4)Å b=6.9922(2)Å c=37.2099(13)Å
α=90° β=90° γ=90°
C19H20NO,NO3
C19H20NO,NO3
CrystEngComm (2018) 20, 24 3318
a=10.4953(9)Å b=19.9612(19)Å c=8.1903(7)Å
α=90° β=90° γ=90°
C20H22NO21,Cl1,2(H2O)
C20H22NO21,Cl1,2(H2O)
CrystEngComm (2018) 20, 24 3318
a=11.5183(3)Å b=24.4350(7)Å c=7.1002(2)Å
α=90° β=98.786(3)° γ=90°
C20H22NO2,NO3,H2O
C20H22NO2,NO3,H2O
CrystEngComm (2018) 20, 24 3318
a=10.9418(7)Å b=22.2438(13)Å c=8.0740(6)Å
α=90° β=99.632(7)° γ=90°
Tetrakis(2-[(E)-2-(2-hydroxy-3-methoxyphenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium) tris(phosphoric acid) nonahydrate tetradihydrogen phosphate
2(C20H22NO2),2(H2O4P),1.5(H3O4P),4.5(H2O)
CrystEngComm (2018) 20, 24 3318
a=12.0289(5)Å b=12.4435(5)Å c=17.4047(7)Å
α=76.128(4)° β=81.814(4)° γ=79.953(4)°
C23H22NO1,Cl1
C23H22NO1,Cl1
CrystEngComm (2018) 20, 24 3318
a=17.6960(6)Å b=15.1030(4)Å c=6.9665(3)Å
α=90° β=92.410(4)° γ=90°
2-[(E)-2-(2-hydroxy-3-methoxyphenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium dihydrate bromide
C20H22NO21,Br1,2(H2O)
CrystEngComm (2018) 20, 24 3318
a=11.5976(3)Å b=23.9015(6)Å c=7.36093(15)Å
α=90° β=98.766(2)° γ=90°
C19H21BrNO1.50
C19H21BrNO1.50
CrystEngComm (2018) 20, 24 3318
a=12.8779(5)Å b=10.4911(5)Å c=12.8498(7)Å
α=90° β=94.836(4)° γ=90°
2-[(E)-2-(2-hydroxy-5-nitrophenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium hydrogen sulfate
C19H19N2O3,HO4S
CrystEngComm (2018) 20, 24 3318
a=11.768(3)Å b=25.295(5)Å c=7.006(2)Å
α=90° β=104.70(3)° γ=90°
C19H19N2O3,NO3
C19H19N2O3,NO3
CrystEngComm (2018) 20, 24 3318
a=7.227(3)Å b=10.0542(10)Å c=12.687(3)Å
α=80.825(14)° β=89.00(2)° γ=88.089(18)°
C19H17N3O5
C19H17N3O5
CrystEngComm (2018) 20, 24 3318
a=18.8741(12)Å b=6.2632(3)Å c=14.2571(7)Å
α=90° β=98.548(6)° γ=90°
C23H22NO,Br
C23H22NO,Br
CrystEngComm (2018) 20, 24 3318
a=17.8583(18)Å b=15.1686(10)Å c=6.9757(3)Å
α=90° β=93.704(7)° γ=90°
C20H22NO2,HO4S
C20H22NO2,HO4S
CrystEngComm (2018) 20, 24 3318
a=7.8327(5)Å b=16.0190(13)Å c=15.1017(19)Å
α=90° β=90° γ=90°
4(C19H19N2O3),2(H3O4P),4(H2O4P),4(C2H3N),H2O
4(C19H19N2O3),2(H3O4P),4(H2O4P),4(C2H3N),H2O
CrystEngComm (2018) 20, 24 3318
a=12.6562(3)Å b=13.9654(7)Å c=28.3803(12)Å
α=83.572(4)° β=79.127(3)° γ=78.777(3)°
1,3,5-trifluoro-2,4,6-triiodobenzene; 2-[(1E)-[(pyridin-3-yl)imino]methyl]phenol 1:1 cocrystal
C12H10N2O,C6F3I3
CrystEngComm (2018) 20, 36 5332
a=24.1738(4)Å b=9.45562(19)Å c=17.8360(3)Å
α=90° β=90° γ=90°
C19H11F4I2NO
C19H11F4I2NO
CrystEngComm (2018) 20, 36 5332
a=5.3298(5)Å b=5.9839(4)Å c=15.276(2)Å
α=90.196(8)° β=93.824(9)° γ=100.428(7)°
2(C12H10N2O),C6F3I3
2(C12H10N2O),C6F3I3
CrystEngComm (2018) 20, 36 5332
a=4.1899(3)Å b=29.106(2)Å c=24.6798(18)Å
α=90° β=92.834(7)° γ=90°
1,2,4,5-tetrafluoro-3,6-diiodobenzene 2-[(1E)-[(pyridin-3-yl)imino]methyl]phenol 1:2 cocrystal
C12H10N2O,0.5(C6F4I2)
CrystEngComm (2018) 20, 36 5332
a=15.3516(5)Å b=5.75781(16)Å c=16.8675(6)Å
α=90° β=105.671(3)° γ=90°
1,2,3,5-tetrafluoro-4,6-diiodobenzene 2-[(1E)-[(pyridin-3-yl)imino]methyl]phenol 1:1 cocrystal
C12H10N2O,C6F4I2
CrystEngComm (2018) 20, 36 5332
a=7.2968(5)Å b=15.2068(12)Å c=19.3646(15)Å
α=110.783(7)° β=91.701(6)° γ=100.999(6)°
C38H38Br4N2O2Zn2
C38H38Br4N2O2Zn2
CrystEngComm (2019) 21, 33 4925
a=9.3000(8)Å b=9.3023(8)Å c=11.3137(10)Å
α=94.166(7)° β=108.407(8)° γ=96.344(7)°
C19H18Cl2N2O3Zn
C19H18Cl2N2O3Zn
CrystEngComm (2019) 21, 33 4925
a=17.659(4)Å b=15.216(3)Å c=6.9834(12)Å
α=90° β=94.06(2)° γ=90°
C19H20NO,Cl3H2OZn
C19H20NO,Cl3H2OZn
CrystEngComm (2019) 21, 33 4925
a=8.2890(5)Å b=21.5395(16)Å c=12.2257(11)Å
α=90° β=97.748(7)° γ=90°
C19H20Cl2N2O4Zn,2(H2O)
C19H20Cl2N2O4Zn,2(H2O)
CrystEngComm (2019) 21, 33 4925
a=12.388(6)Å b=13.671(7)Å c=14.855(8)Å
α=108.02(5)° β=101.20(4)° γ=101.01(4)°
Zinc(2+) ion 2-[(E)-2-(3-methoxy-2-oxidophenyl)ethenyl]-1,3,3-trimethyl-3H-indol-1-ium ethanol dibromide
C20H20NO2,Zn2,2(Br1),C2H6O1
CrystEngComm (2019) 21, 33 4925
a=10.1512(3)Å b=12.0717(4)Å c=21.8754(7)Å
α=84.876(3)° β=77.406(2)° γ=65.333(3)°
Zinc(2+) ion bis(1,3,3-trimethyl-2-[(E)-2-(5-nitro-2-oxidophenyl)ethenyl]-3H-indol-1-ium) dichloride
2(C19H18N2O3),Zn2,2Cl1
CrystEngComm (2019) 21, 33 4925
a=8.86510(16)Å b=14.8667(4)Å c=15.2523(5)Å
α=113.831(3)° β=94.587(2)° γ=91.7161(19)°
Dizinc(2+) ion bis(1,3,3-trimethyl-2-[(E)-2-(2-oxidonaphthalen-1-yl)ethenyl]-3H-indol-1-ium) tetrabromide acetone solvate
C46H42Br4N2O2Zn2,C3H6O
CrystEngComm (2019) 21, 33 4925
a=8.97440(14)Å b=12.9849(2)Å c=20.5608(3)Å
α=90° β=91.4476(14)° γ=90°
2(C22H27Cl2NO3Zn),H2O
2(C22H27Cl2NO3Zn),H2O
CrystEngComm (2019) 21, 33 4925
a=21.9384(11)Å b=9.7692(4)Å c=21.2029(10)Å
α=90° β=97.634(5)° γ=90°
C19H18Br2N2O3Zn
C19H18Br2N2O3Zn
CrystEngComm (2019) 21, 33 4925
a=17.517(7)Å b=15.290(4)Å c=7.252(2)Å
α=90° β=92.47(3)° γ=90°
C19H20Cl2N2O4Zn,2(H2O)
C19H20Cl2N2O4Zn,2(H2O)
CrystEngComm (2019) 21, 33 4925
a=6.5663(8)Å b=15.8090(12)Å c=20.1333(15)Å
α=90° β=90° γ=90°
2(C21H21Br2N3O3Zn),C2H3N
2(C21H21Br2N3O3Zn),C2H3N
CrystEngComm (2019) 21, 33 4925
a=14.4022(7)Å b=13.0338(6)Å c=26.6165(16)Å
α=90° β=99.770(6)° γ=90°
2(C19H19N2O3),Cl4Co,H2O
2(C19H19N2O3),Cl4Co,H2O
CrystEngComm (2019) 21, 33 4925
a=11.6156(11)Å b=13.0124(6)Å c=14.0058(14)Å
α=77.862(6)° β=76.661(8)° γ=87.030(6)°
C19H18Cl3CoN2O3,C19H19N2O3
C19H18Cl3CoN2O3,C19H19N2O3
CrystEngComm (2019) 21, 33 4925
a=11.9195(9)Å b=12.6137(7)Å c=25.1143(14)Å
α=90° β=97.136(6)° γ=90°
C20.07H21.22Br2.46N2O3.54Zn,C19H18.46N2O3
C20.07H21.22Br2.46N2O3.54Zn,C19H18.46N2O3
CrystEngComm (2019) 21, 33 4925
a=11.8302(4)Å b=12.7363(3)Å c=24.6870(9)Å
α=90° β=98.600(3)° γ=90°
C21H25N3O4S
C21H25N3O4S
Journal of the Chemical Society, Perkin Transactions 2 (2002) 5 1012
a=5.8940(10)Å b=37.138(6)Å c=9.730(2)Å
α=90.00° β=91.827(16)° γ=90.00°
C18H16N3O3S
C18H16N3O3S
Journal of the Chemical Society, Perkin Transactions 2 (2002) 5 1012
a=6.2610(13)Å b=8.4800(17)Å c=16.433(3)Å
α=86.75(3)° β=82.94(3)° γ=81.98(3)°
Tetrakis(N-methylimidazole)copper(II) bistriflimide
C22H32CuF6N9O4S2,C2F6NO4S2
CrystEngComm (2012) 14, 15 4902
a=8.991(2)Å b=9.438(3)Å c=14.654(3)Å
α=89.594(15)° β=72.209(13)° γ=62.905(13)°
Tetrakis(N-methylimidazole)copper(II) bistriflimide
C32H48CuF12N10O8S4
CrystEngComm (2012) 14, 15 4902
a=16.0369(6)Å b=24.0453(9)Å c=25.0434(9)Å
α=90.00° β=90.651(2)° γ=90.00°
Hexakis(N-methylimidazole)cobalt(II) bistriflimide
C24H36CoN12,2(C2F6NO4S2)
CrystEngComm (2012) 14, 15 4902
a=8.2207(2)Å b=20.3211(4)Å c=27.0612(5)Å
α=90.00° β=92.363(2)° γ=90.00°
Hexakis(N-methylimidazole)nickel(II) bistriflimide
C24H36N12Ni,2(C2F6NO4S2)
CrystEngComm (2012) 14, 15 4902
a=8.2018(2)Å b=20.3183(5)Å c=26.9380(8)Å
α=90.00° β=92.341(3)° γ=90.00°
Hexakis(N-methylimidazole)copper(II) bistriflimide
C24H36CuN12,2(C2F6NO4S2)
CrystEngComm (2012) 14, 15 4902
a=8.2933(3)Å b=11.1971(3)Å c=24.1682(7)Å
α=91.145(1)° β=93.419(1)° γ=92.945(2)°
L-Prolinium cocrystal of S-Naproxen
C14H14O3,C5H9NO2
CrystEngComm (2013) 15, 17 3341
a=5.6999(2)Å b=6.5428(3)Å c=23.1874(10)Å
α=90.00° β=94.835(4)° γ=90.00°
D-Prolinium cocrystal of S-Naproxen
C14H14O3,C5H9NO2
CrystEngComm (2013) 15, 17 3341
a=5.7713(2)Å b=6.2520(3)Å c=23.8346(11)Å
α=90.00° β=92.047(4)° γ=90.00°
DL-Prolinium cocrystal of RS-Naproxen
C14H14O3,C5H9NO2,H2O
CrystEngComm (2013) 15, 17 3341
a=6.1054(2)Å b=12.4750(5)Å c=49.1664(13)Å
α=90.00° β=90.00° γ=90.00°
L-Prolinium cocrystal of RS-Naproxen
C14H14O3,C5H9NO2,H2O
CrystEngComm (2013) 15, 17 3341
a=13.122(2)Å b=5.8980(10)Å c=24.075(3)Å
α=90.00° β=95.560(5)° γ=90.00°
Clofaziminium (1+) diclofenac (1-) ethanol solvate
C27H23Cl2N4,C14H10Cl2NO2,C2H6O
CrystEngComm (2020)
a=12.5325(5)Å b=13.1139(3)Å c=13.1773(4)Å
α=82.032(2)° β=71.833(3)° γ=74.538(3)°
CaCl2 etiracetam Isonicotinamide
C22H36CaN6O6,2(Cl)
Chemical communications (Cambridge, England) (2020) 56, 86 13229-13232
a=7.968(2)Å b=12.170(4)Å c=15.304(4)Å
α=87.17(2)° β=86.30(2)° γ=74.76(2)°
RS-naproxen L-proline 1:2 cocrystal
C14H14O3,2(C5H9NO2)
CrystEngComm (2018) 20, 45 7308
a=5.84172(9)Å b=8.98394(13)Å c=45.6816(8)Å
α=90° β=90° γ=90°
C46H42Cl4N2O2Zn2,C3H6O
C46H42Cl4N2O2Zn2,C3H6O
CrystEngComm (2019) 21, 33 4925
a=8.8991(3)Å b=13.0969(4)Å c=19.8630(6)Å
α=90° β=90.033(3)° γ=90°
C19H18Cl3N2O3Zn,C19H19N2O3
C19H18Cl3N2O3Zn,C19H19N2O3
CrystEngComm (2019) 21, 33 4925
a=11.8909(7)Å b=12.6582(7)Å c=25.0471(16)Å
α=90° β=98.073(6)° γ=90°
C38H36Br2N4O6Zn
C38H36Br2N4O6Zn
CrystEngComm (2019) 21, 33 4925
a=9.1737(6)Å b=14.9690(14)Å c=15.421(2)Å
α=116.717(11)° β=98.405(8)° γ=89.487(7)°
Tetrakis(N-methylimidazole)copper(II) bistriflimide
C20H24CuF12N10O8S4
CrystEngComm (2012) 14, 15 4902
a=9.1104(5)Å b=9.6323(5)Å c=10.6590(7)Å
α=68.139(4)° β=85.255(5)° γ=87.828(4)°
(E)-2-methoxy-6-{[(3-nitrophenyl)imino]methyl}phenol
C14H12N2O4
CrystEngComm (2015) 17, 18 3509
a=4.7895(3)Å b=11.3446(10)Å c=12.0610(9)Å
α=93.472(7)° β=100.357(6)° γ=94.022(6)°
(E)-2-methoxy-6-{[(3-nitrophenyl)imino]methyl}phenol
C14H12N2O4
CrystEngComm (2015) 17, 18 3509
a=12.8418(3)Å b=7.5487(2)Å c=26.4610(6)Å
α=90.00° β=90.00° γ=90.00°
P3-PolymorphI-Pbca
C14H12N2O4
CrystEngComm (2015) 17, 18 3509
a=12.4915(15)Å b=7.5972(14)Å c=26.1737(18)Å
α=90.00° β=90.00° γ=90.00°
Piracetam LiBr 2H2O
C6H14BrLiN2O4
Chem.Commun. (2012) 48, 8219
a=7.7723(5)Å b=9.8812(7)Å c=14.8483(11)Å
α=90.00° β=90.404(6)° γ=90.00°
C6H14ClLiN2O4
C6H14ClLiN2O4
Chem.Commun. (2012) 48, 8219
a=7.5347(11)Å b=9.7992(12)Å c=14.732(3)Å
α=90.00° β=91.596(13)° γ=90.00°
C6H10N2O2Li1Cl1
C6H10N2O2Li1Cl1
Chem.Commun. (2012) 48, 8219
a=9.1230(1)Å b=12.1788(2)Å c=8.1089(2)Å
α=90° β=101.8548(8)° γ=90°
C56H32EuF12O8,C8H20N
C56H32EuF12O8,C8H20N
Chem.Commun. (2011) 47, 1625
a=12.1252(10)Å b=21.996(2)Å c=12.8415(10)Å
α=90.00° β=117.955(10)° γ=90.00°
C21H20Cl2FNO
C21H20Cl2FNO
Journal of the Chemical Society, Perkin Transactions 2 (2000) 9 1781
a=13.806(3)Å b=14.761(3)Å c=9.6180(19)Å
α=90.00° β=92.77(3)° γ=90.00°
C16H13NO2
C16H13NO2
CrystEngComm (2015) 17, 12 2523
a=9.837(2)Å b=16.124(4)Å c=8.643(3)Å
α=90.00° β=90.00° γ=90.00°
4(C17H13NO4),C7H7
4(C17H13NO4),C7H7
CrystEngComm (2015) 17, 12 2523
a=8.3591(3)Å b=10.4196(7)Å c=19.0455(9)Å
α=88.407(5)° β=88.481(3)° γ=76.340(4)°